One of the best things about stockpicking, is that you get the chance to research amazing technologies.
No more so than from CEO Alastair Smith, who yesterday kindly ran me through how Avacta is breaking new ground in medical science, alongside providing details on the companyâ€™s exciting 3rd party royalty & licensing programs.
Indeed the immense versatility & applicability of its 2 cutting edge platforms across enormous addressable markets is frankly astounding. Alastair was fabulous again.
Some might find this interesting, a poster from ADVFN got invited onto a podcast and talks about AVCT, doesn’t say anything that the well researched already know but it will have got the company out to a wider audience.
I agree around the end of this quarter could be any day now, equally I would caution that it could be in the first couple of weeks in April. Knowing how timelines have slipped best not allow the derampers any headroom by setting 31st March in tablets of stone